In this study, we investigated whether the TLR7/8 agonist R848 elicits anti-tumor responses in syngeneic orthotopic (OT) murine PDAC models and whether this class of therapy is beneficial or harmful toward PDAC-associated cachexia. This evidence concerns the gene TLR7 and neoplasm.